Abbott Announces CE Mark and European Launch of Next-Generation XIENCE Xpedition™ Drug Eluting Stent
August 20, 2012
Abbott Park, Illinois (NYSE: ABT) — Abbott today announced that the XIENCE Xpedition™ Everolimus Eluting Coronary Stent System received CE Mark in Europe for the treatment of coronary artery disease.Read More
Abbott Park, Illinois (NYSE: ABT) — Abbott today announced that the XIENCE Xpedition™ Everolimus Eluting Coronary Stent System received CE Mark in Europe for the treatment of coronary artery disease.Read More
Post a Comment